SCHEMBL3427848

SCHEMBL3427848

CC(CCN(C)C)c1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 4/20 0.69
HRH1 P35367 4/20 0.69
AOC3 Q16853 1/20 0.53
RIPK1 Q13546 1/20 0.53
CHRM2 P08172 2/20 0.51
SLC6A2 P23975 2/20 0.51
SLC6A4 P31645 2/20 0.51
SCN1A P35498 2/20 0.51
SCN2A Q99250 2/20 0.51
SCN3A Q9NY46 2/20 0.51
TAAR1 Q96RJ0 2/20 0.50
LMNA P02545 2/20 0.50
CYP1A2 P05177 1/20 0.50
CHRM4 P08173 1/20 0.50
CHRM5 P08912 1/20 0.50
ADRA2A P08913 1/20 0.50
CYP2D6 P10635 1/20 0.50
CHRM1 P11229 1/20 0.50
TSHR P16473 1/20 0.50
ADRA2B P18089 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19121804 1.00 HTR2A (0.69) HTR2AHRH1AOC3RIPK1CHRM2
SCHEMBL22515947 1.00 HTR2A (0.69) HTR2AHRH1AOC3RIPK1CHRM2
SCHEMBL11488300 0.88 HTR2A (0.55) HTR2AHRH1
SCHEMBL11566877 0.88 HTR2A (0.71) HTR2AHRH1AOC3RIPK1CHRM2
SCHEMBL17451533 0.84 RIPK1 (0.55) HTR2AHRH1AOC3RIPK1TAAR1
SCHEMBL11379245 0.84 HTR2A (0.50) HTR2AHRH1AOC3RIPK1CHRM2
SCHEMBL11486794 0.84 LTA4H (0.56) HTR2AHRH1
SCHEMBL1802493 0.82 HRH1 (1.00) HTR2AHRH1CHRM2SLC6A2SLC6A4
SCHEMBL14064905 0.82 AOC3 (0.48) HTR2AHRH1AOC3RIPK1TAAR1
SCHEMBL6280516 0.81 RIPK1 (0.67) AOC3RIPK1CHRM2SLC6A2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1187244-A2 Organic amines as additives for electrochemical cells MERCK PATENT GmbH (DE) 2002-03-13 EP claimed
US-20230357249-A1 ANDROGEN RECEPTOR PROTEIN DEGRADERS WITH A TRICYCLIC CEREBLON LIGAND UNIV MICHIGAN REGENTS (US) 2023-11-09 US disclosed
US-20230357249-A1 ANDROGEN RECEPTOR PROTEIN DEGRADERS WITH A TRICYCLIC CEREBLON LIGAND UNIV MICHIGAN REGENTS (US) 2023-11-09 US disclosed
US-20170266167-A1 ERK INHIBITORS MERCK SHARP & DOHME CORP. (US) 2017-09-21 US disclosed
US-8883828-B2 2-aminopyridine analogs as glucokinase activators ARRAY BIOPHARMA INC. (US) 2014-11-11 US disclosed
US-20100323098-A1 ELECTRODE MATERIAL FOR RECHARGEABLE LITHIUM BATTERY, ELECTRODE STRUCTURAL BODY COMPRISING SAID ELECTRODE MATERIAL, RECHARGEABLE LITHIUM BATTERY HAVING SAID ELECTRODE STRUCTURAL BODY, PROCESS FOR THE PRODUCTION OF SAID ELECTRODE STRUCTURAL BODY, AND PROCESS FOR THE PRODUCTION OF SAID RECHARGEABLE LITHIUM BATTERY CANON KABUSHIKI KAISHA (JP) 2010-12-23 US disclosed
US-7803290-B2 Electrode material for rechargeable lithium battery, electrode structural body comprising said electrode material, rechargeable lithium battery having said electrode structural body, process for the production of said electrode structural body, and process for the production of said rechargeable lithium battery CANON KABUSHIKI KAISHA (JP) 2010-09-28 US disclosed
WO-2008062473-A1 PROCESS FOR PREPARING ATOMOXETINE HYDROCHLORIDE CADILA HEALTHCARE LIMITED (IN) 2008-05-29 WO disclosed
US-20080090152-A1 Electrode material for rechargeable lithium battery, electrode structural body comprising said electrode material, rechargeable lithium battery having said electrode structural body, process for the production of said electrode structual body, and process for the production of said rechargeable lithium battery CANON KABUSHIKI KAISHA (JP) 2008-04-17 US disclosed
US-7316792-B2 Electrode material for rechargeable lithium battery and electrode structural body comprising said electrode material CANON KABUSHIKI KAISHA (JP) 2008-01-08 US disclosed
US-7141187-B2 Electrode material for rechargeable lithium battery, electrode structural body comprising said electrode material, rechargeable lithium battery having said electrode structural body, process for the production of said electrode structural body, and process for the production of said rechargeable lithium battery CANON KABUSHIKI KAISHA (JP) 2006-11-28 US disclosed
US-20060237697-A1 Electrode material for rechargeable lithium battery, electrode structural body comprising said electrode material, rechargeable lithium battery having said electrode structural body, process for the production of said electrode structural body, and process for the production of said rechargeable lithium battery CANON KABUSHIKI KAISHA (JP) 2006-10-26 US disclosed
US-20030157407-A1 Electrode material for rechargeable lithium battery, electrode structural body comprising said electrode material, rechargeable lithium battery having said electrode structural body, process for the production of said electrode structural body, and process for the production of said rechargeable lithium battery CANON KABUSHIKI KAISHA (JP) 2003-08-21 US disclosed
EP-1313158-A2 Electrode material for rechargeable lithium battery, electrode comprising said electrode material, rechargeable lithium battery having said electrode , and process for the production thereof CANON KABUSHIKI KAISHA (JP) 2003-05-21 EP disclosed
EP-1187244-A2 Organic amines as additives for electrochemical cells MERCK PATENT GmbH (DE) 2002-03-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357249-A1 ANDROGEN RECEPTOR PROTEIN DEGRADERS WITH A TRICYCLIC CEREBLON LIGAND AR, GPER1, CRBN HTR2A 264/4885HRH1 2651/4885AOC3 997/4885
US-20170266167-A1 ERK INHIBITORS MAPK1, MAPK3, MAPK6 HTR2A 4554/4885HRH1 1861/4885AOC3 4513/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.